Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune-Mediated Diseases

Lead Pharma, a clinical stage pharmaceutical company and community member at Pivot Park in Oss, announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune-mediated diseases. In this single target research collaboration Lead Pharma and Roche will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for further development and global commercialization. Lead Pharma may receive payments of up to €260 million, plus royalties on worldwide sales. Read the whole Press Release here.